With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life sciences companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
The most recognizable name on the list is ancestry and health company 23andMe. Known best for their “spit tests” that reveal clients genetic background, the company not only breaks down ethnic roots but also provides important health insights for disease risk. READ MORE